Call:+1 7755157689
March 9, 2025


Contact Us

Issue 10

Subclinical thyroiditis related to COVID-19: A case report and literature review

COVID-19 can cause different clinical manifestation by affecting different organs in the body. Involvement of thyroid gland is very rare in COVID-19 infection than any other systems of the body. We described a 41-year-old female with subclinical thyroiditis most likely related to corona virus infection and reviewed literatures regarding cases of thyroiditis due to COVID-19 have been reported. The objective of this article is to create awareness regarding this novel entity and the association with thyroid dysfunction.

Subclinical thyroiditis related to COVID-19: A case report and literature review Read More »

MANDIBULOFACIAL DYSOSTOSIS GUION-ALMEIDA TYPE: A SYNDROME TO RECOGNIZE IN PRENATAL

Mandibulofacial dysostosis with microcephaly, Guion-Almeida type (MFDGA) is a rare multiple congenital anomalies syndrome characterized by malar and mandibular hypoplasia, microcephaly, ear malformations with associated conductive hearing loss, esophageal atresia, cleft palate and distinctive facial dysmorphism. Almost all affected individuals have developmental delay and intellectual disability.

MANDIBULOFACIAL DYSOSTOSIS GUION-ALMEIDA TYPE: A SYNDROME TO RECOGNIZE IN PRENATAL Read More »

Acquired SAMD5-RET fusion-mediated resistance to gefitinib in metastatic non-small cell lung cancer harboring EGFR-activating mutation: a case report

Patients with disease progression on first-generation tyrosine kinase inhibitors (TKIs) usually have a poor prognosis. The mechanisms of acquired resistance to epidermal growth factor receptor (EGFR)-TKIs have been widely reported; however, reports of acquired

Acquired SAMD5-RET fusion-mediated resistance to gefitinib in metastatic non-small cell lung cancer harboring EGFR-activating mutation: a case report Read More »

Over 5 years of complete antiandrogen withdrawal response in a patient with prostate cancer: A case report

Progressive prostate cancer is primarily treated with androgen-deprivation therapy. The antiandrogen withdrawal (AAW) response (AAWR) is defined as subjective and/or objective improvement following antiandrogen cessation in patients with elevated prostate-specific antigen (PSA) levels treated with combined androgen blockade (CAB).

Over 5 years of complete antiandrogen withdrawal response in a patient with prostate cancer: A case report Read More »

You cannot copy content of this page